Avalon Globocare: Rises on partnership with GE Healthcare

Change Agents

22/07/2019 22:29

** Shares of the developer of cell-based technologies and
therapeutics  AVCO.O  gain ~22% to $2.50 after market on
strategic partnership with GE Healthcare
    ** Partnership enables Avalon to accelerate its clinical
programs in cellular immunotherapy and stem cell-derived
exosome-based regenerative therapeutics - CEO David Jin
 urn:newsml:reuters.com:*:nGNX80R8yl    
    ** Deal to also help Avalon improve manufacturing, ease
costs and minimize variability in the automated and standardized
bio-production process of clinical-grade cellular products 
        ** Up to Monday's close, stock down 25.5% YTD 

 (Reporting by Shanti S Nair in Bengaluru)
 ((Reuters Messaging:
shantis.nair.thomsonreuters.com@reuters.net))